このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Y-mAbs Therapeutics マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Mike Rossi

最高経営責任者

US$3.1m

報酬総額

CEO給与比率	3.5%
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	5.3yrs
取締役会の平均在任期間	6.5yrs

経営陣の近況

Recent updates

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12

CEO報酬分析

Y-mAbs Therapeutics の収益と比較して、Mike Rossi の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$3m	US$110k	-US$21m

報酬と市場: Mikeの総報酬 ($USD 3.11M ) は、 US市場 ($USD 2.45M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Mikeの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Mike Rossi (53 yo)

less than a year

在職期間

US$3,110,553

報酬

Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Michael Rossi	CEO, President & Director	less than a year	US$3.11m	データなし
Thomas Gad	Founder	9.2yrs	US$2.45m	0.76% $ 4.0m
Bo Kruse	Executive VP	9yrs	US$1.06m	0.42% $ 2.2m
Susan Smith	Senior VP & Chief Commercial Officer	2.4yrs	US$887.28k	0.0097% $ 50.6k
Joris Wiel Wilms	Senior VP & COO	6.6yrs	データなし	0.014% $ 70.7k
Torben Lund-Hansen	Senior VP & CTO	8.4yrs	データなし	0.12% $ 614.5k
Courtney Dugan	Vice President of Investor Relations	no data	データなし	データなし
Vignesh Rajah	Senior VP & Chief Medical Officer	4yrs	US$724.92k	0.019% $ 101.1k
Norman D. LaFrance	Chief Development Officer	no data	データなし	データなし

5.3yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: YMABの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Michael Rossi	CEO, President & Director	less than a year	US$3.11m	データなし
Thomas Gad	Founder	9.2yrs	US$2.45m	0.76% $ 4.0m
James Healy	Independent Chairman of the Board	6.6yrs	US$184.31k	0.064% $ 334.8k
David Gill	Independent Director	6.5yrs	US$180.56k	0.0053% $ 27.8k
Mary Tagliaferri	Director	less than a year	データなし	0% $ 0
Johan Wedell-Wedellsborg	Independent Director	8.8yrs	US$158.06k	0.0053% $ 27.8k
Ashutosh Tyagi	Independent Director	6.6yrs	US$158.06k	0.0053% $ 27.8k
Laura Hamill	Independent Director	4yrs	US$168.06k	0.0053% $ 27.8k

6.5yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: YMABの取締役会は経験豊富であると考えられます ( 6.5年の平均在任期間)。

Y-mAbs Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Founder notifies of intention to sell stock

Founder recently sold US$841k worth of stock

Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer

Executive VP notifies of intention to sell stock

Founder recently sold US$396k worth of stock

Founder notifies of intention to sell stock

Recent updates

Founder notifies of intention to sell stock

Founder recently sold US$841k worth of stock

Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Executive VP notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Announces New Interim Analysis of Phase 2 Data for Naxitamab At 2024 Asco Annual Meeting

Founder recently sold US$396k worth of stock

Founder notifies of intention to sell stock

Y-mAbs: There's A Ceiling Here Somewhere

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Y-mAbs Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Y-mAbs Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024

Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Consensus estimates of losses per share improve by 42%

Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Y-mAbs Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Price target increased by 9.3% to US$13.67

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Founder exercised options to buy US$370k worth of stock.

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$795k worth of stock

Founder notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Y-mAbs Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Y-mAbs Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective from November 6, 2023

Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma

Consensus EPS estimates upgraded to US$0.70 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Y-mAbs Therapeutics, Inc. Announces DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil

Consensus revenue estimates increase by 27%

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Price target increased by 11% to US$10.50

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Updates Financial Guidance for the Full-Year 2023

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Consensus estimates of losses per share improve by 14%

Price target decreased by 15% to US$9.14

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Y-mAbs Therapeutics, Inc. and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

Rosen Law Firm Encourages Y-Mabs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB

Price target decreased to US$10.88

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Y-mAbs Therapeutics, Inc. Announces National Medical Products Administration in China Has Granted Danyelza 40Mg/10Ml Conditional Approval

Y-mAbs Therapeutics, Inc. Announces Complete Response Letter for Omburtamab Biologics License Application

Price target decreased to US$12.00

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2022

Y-mAbs Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Consensus EPS estimates fall by 18%

Y-mAbs Therapeutics Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

Y-mAbs Therapeutics, Inc Announces Pivotal Data for Omburtamab

Y-Mabs Therapeutics, Inc. Announces Scheduling of Fda Advisory Committee Meeting for Omburtamab

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

Consensus EPS estimates fall by 16%

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2022

マネジメント基準チェック /34